XM does not provide services to residents of the United States of America.

STOXX 600 recovers early losses on US jobs data relief



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-STOXX 600 recovers early losses on US jobs data relief</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window

Novo rebounds on positive read-across from Lilly

Siemens jumps after profit beat

Allianz rises on Q2 beat

Deutsche Telekom up after increase in Q2 core earnings

STOXX 600 up 0.1%

Updates at 1600 GMT

By Ankika Biswas and Pranav Kashyap

Aug 8 (Reuters) -Europe's benchmark stock index recouped early losses to close slightly higher on Thursday, helped by encouraging U.S. jobs market data and as the heavy-weight healthcare sector got a boost from Novo Nordisk's recovery.

The STOXX 600 .STOXX closed 0.1% higher, after a sharp early decline in technology stocks knocked the pan-European index down over 1% intraday.

Data showed weekly U.S. jobless claims fell more than expected, suggesting fears of a sharp weakening in the labour market, which in part had fuelled U.S. recession fears, were overblown.

"Just because the labour market is cooling off doesn't mean we're (U.S.) entering into a recession. While there has been renewed worry about the labour market, we believe it's overblown," said from Skyler Weinand, chief investment officer, Regan Capital.

As European stocks recovered after the data, Wall Street also enjoyed strong gains for the day.

The STOXX 600 has been volatile this week as investors evaluated fears of a potential U.S. recession and looked for clear macroeconomic signals, both at home and globally.

German inflation data, due on Friday, will give investors a clearer picture on Europe's largest economy as it teeters on the verge of a recession.

Europe's largest company by market value, Novo Nordisk NOVOb.CO, rose 4.3%, recovering more than half of Wednesday's near 7% slide, as rival Eli Lilly's LLY.N raised its annual sales forecast, boding well for the Danish drug maker.

Healthcare .SXDP was among the top sectoral gainers, also boosted by a 8.3% jump in British drugmaker Hikma Pharmaceuticals HIK.L on an upbeat annual outlook, while media .SXMP was the worst hit sector.

Allianz ALVG.DE gained 2% after the German insurer posted a better-than-expected rise in second-quarter net profit and said it was on track to meet its full-year target.

Several other European insurers recorded bumper first-half profits on Thursday, such as Zurich Insurance ZURN.S, Munich Re MUVGn.DE and London's Beazley BEZG.L.

Siemens SIEGn.DE rose 2.1% after beating quarterly earnings forecasts.

Deutsche Telekom DTEGn.DE was up 1.9% after the telecom firm reported a 7.8% increase in its second-quarter core earnings, while Entain ENT.L climbed 5% as the British gambling group raised its annual revenue forecast.

Meanwhile, valve maker Spirax-Sarco Engineering SPX.L dropped 7.4% after results, while German sportswear maker Puma PUMG.DE fell 4% as a raft of brokerage price-target cuts followed Wednesday's dismal earnings.



Reporting by Pranav Kashyap and Ankika Biswas in Bengaluru; Editing by Sonia Cheema, Varun H K and Christina Fincher

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.